Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 48433-033

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 48433-033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Safecor Health, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium Er Tablets, Usp 250 mg Unit Carton Label (Image 01)

This is a description of Divalproex Sodium extended-release tablets, USP. They are used for Valproic Acid Activity with a once-daily dosing regimen. The typical dosage is 250mg. The text also includes storage instructions and manufacturer information for Hylan Pharmaceuticals Inc.*

FDA Label Image

Unit Carton (Image 02)

This text seems to be a description of a product package containing medication, likely a prescription medicine. It includes information about child resistance, institutional use, and contact details for the distributing company Safecor Health LLC. The package also mentions an expiration date and an identifying number. It is essential to keep the medication out of the reach of children. The company can be contacted at the provided toll-free number or website.*

FDA Label Image

Divalproex Structural Formula (Image 03)

FDA Label Image

Figure 1: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Adjunctive Therapy Stud (Image 04)

This text describes a chart showing the percentage reduction in CP$ rate in relation to the percentage of patients experiencing improvement, no change, or worsening. The chart likely provides a visual representation of how the CP$ rate reduction corresponds to different patient outcomes.*

FDA Label Image

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)

This text appears to describe a comparison between different doses of a drug (Divalproex Sodium) for delayed release in patients. The analysis indicates variations in the percentage of patients categorized under each dosage category, such as low dose, high dose, and a group labeled as "No Change." The data highlights the distribution of patients across these dosage groups, including the percentage distribution for each category.*

FDA Label Image

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Image 06)

This is not readable.*

FDA Label Image

Divalproex Sodium Er Tablets, Usp 500 mg Unit Carton Label (Image 07)

This is information about Divalproex Sodium Extended-Release Tablets, USP with a dosage of 500 mg for once-daily dosing. The tablets contain Valproic Acid Activity and are used as prescribed by the doctor. It is recommended to store the tablets at a temperature of 20° to 25°C (68° to 77°F).*

FDA Label Image

Unit Carton (Image 08)

This text appears to be a description or label of a product, possibly a medicine or pharmaceutical product. It contains information such as warnings on child safety, storage instructions, and contact details for the distributing company "Safecor Health LLC". The product is mentioned to be not child resistant, for institutional use only. The package provides light resistance and includes an expiration date. It is recommended to keep the product out of the reach of children. For more information, you can contact Safecor Health LLC at the provided phone number or visit their website.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.